Keywords
monocyte chemoattractant protein-1, diabetic nephropathy.
How to Cite
Topchij, I., Semenovykh, P., Galchinskaya, V., & Yakimenko, Y. (2013). Disturbances in monocyte chemoattractant protein production in patients w ith diabetic nephropathy. Endokrynologia, 18(2), 45-49. Retrieved from https://endokrynologia.com.ua/index.php/journal/article/view/390
Abstract
Our data showed that diabetic nephropathy (DN) is accompanied by significant growth of monocyte chemoattractant protein-1 (MСP-1) in blood plasma of patients with the initial stages of the disease. Progressing of the disease went along with the further increase of MСP-1 concentration in patients with advanced
stages of DN. The revealed increase of MСP-1 blood plasma level in patients with DN may be a marker of inflammatory and sclerotic changes in renal tissue and causes more active application of specific anti-inflammatory therapy for these patients.
References
1. Дудар І.О., Мюнталь О.М. Діабетична нефропатія та фактори її прогресування // Укр. журн. нефрол. діал. 2006, № 1(8), 35-38.
2. Eddy A.A. Progression in chronic kidney disease // Adv. Chronic Kidney Dis. 2005, 12, 353-365.
3. Williams T.M., Little M.H., Ricardo S.D. Macrophages in renal development, injury, and repair // Semin. Nephrol. 2010, 30(3), 255-267.
4. Vernon M.A., Mylonas K.J., Hughes J. Macrophages and renal fibrosis // Semin. Nephrol. 2010, 30(3), 302-317.
5. Tesch G.H. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy // Am. J. Physiol. Renal Physiol. 2008, 294, 697-701.
6. Giunti S., Barutta F., Perin P.C., Gruden G. Targeting the MCP-1/CCR2 System in diabetic kidney disease // Curr. Vasc. Pharmacol. 2010, 8(6), 849-860.
7. Chiarelli F., Cipollone F., Mohn A. et al. Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes // Diabetes
Care. 2002, 25, 1829-1834.
8. Takebayashi K., Matsumoto S., Aso Y., Inukai T. Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in nonobese
Type 2 diabetic patients // J. Diabetes Complications. 2006, 20(2), 98-104.
9. Chow F.Y., Nikolic-Paterson D.J., Ma F.Y. et al. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice // Diabetologia. 2007, 50, 471-480.
10. Matsushita Y., Ogawa D., Wada J. Activation of peroxisome proliferator-activated receptor delta inhibits streptozotocin-induced diabetic nephropathy through
anti-inflammatory mechanisms in mice // Diabetes. 2011, 60(3), 960-968.
2. Eddy A.A. Progression in chronic kidney disease // Adv. Chronic Kidney Dis. 2005, 12, 353-365.
3. Williams T.M., Little M.H., Ricardo S.D. Macrophages in renal development, injury, and repair // Semin. Nephrol. 2010, 30(3), 255-267.
4. Vernon M.A., Mylonas K.J., Hughes J. Macrophages and renal fibrosis // Semin. Nephrol. 2010, 30(3), 302-317.
5. Tesch G.H. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy // Am. J. Physiol. Renal Physiol. 2008, 294, 697-701.
6. Giunti S., Barutta F., Perin P.C., Gruden G. Targeting the MCP-1/CCR2 System in diabetic kidney disease // Curr. Vasc. Pharmacol. 2010, 8(6), 849-860.
7. Chiarelli F., Cipollone F., Mohn A. et al. Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes // Diabetes
Care. 2002, 25, 1829-1834.
8. Takebayashi K., Matsumoto S., Aso Y., Inukai T. Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in nonobese
Type 2 diabetic patients // J. Diabetes Complications. 2006, 20(2), 98-104.
9. Chow F.Y., Nikolic-Paterson D.J., Ma F.Y. et al. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice // Diabetologia. 2007, 50, 471-480.
10. Matsushita Y., Ogawa D., Wada J. Activation of peroxisome proliferator-activated receptor delta inhibits streptozotocin-induced diabetic nephropathy through
anti-inflammatory mechanisms in mice // Diabetes. 2011, 60(3), 960-968.
Downloads
Download data is not yet available.